Brief: WILEX AG adjusts FY guidance

Heidelberg Pharma AG

10/10/2017 06:04

Oct 10 (Reuters) -  WILEX AG   WL6G.DE : 
    * SAID ON MONDAY ANNOUNCED THAT IT HAS ADJUSTED ITS GUIDANCE 
FOR CURRENT FISCAL YEAR, WHICH WAS PUBLISHED IN MARCH 2017 
    * SAID SALES REVENUES ARE DOWNWARD ON ONE HAND DUE TO 
DEFERRED REVENUE ARISING UNDER TAKEDA AGREEMENT, AS FIRST 
PAYMENT HAD TO BE SPLIT IN FAVOR OF COMING QUARTERS 
    * SAID ON THE OTHER HAND THERE IS A POSTPONEMENT OF 
MILESTONE PAYMENTS FROM LINK HEALTH 
    * WILEX GROUP EXPECTS TO GENERATE BETWEEN EUR 2.0 MILLION 
AND EUR 3.0 MILLION IN SALES REVENUE AND OTHER INCOME 
(PREVIOUSLY: EUR 4.0 MLN TO EUR 6.0 MLN) FOR FY 2017  
    * OPERATING EXPENSES ARE NOW EXPECTED TO BE IN THE RANGE OF 
EUR 12.0 MLN TO EUR 14.0 MLN (PREVIOUSLY: EUR 11.0 MLN TO EUR 
15.0 MLN) 
    * FY EBIT IS NOW EXPECTED TO BE BETWEEN EUR -9.0 AND EUR 
-11.0 MILLION(PREVIOUSLY: EUR -6.0 MILLION TO EUR -10.0 MILLION) 
    * SAID WILEX WILL REQUIRE ADDITIONAL FUNDS TO IMPLEMENT THE 
ACTIVITIES PLANNED IN CONNECTION WITH ITS PROPRIETARY ATAC 
PROJECTS 
    * SAID BELIEVES IT HAS SUFFICIENT FUNDS TO FINANCE 
OPERATIONS UNTIL THE SECOND QUARTER OF 2018 
 
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nEQb7dftma 
     
 Further company coverage:  WL6G.DE   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))